Dataset opportunity
Elucidbio — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Elucidbio, usable for Diagnostic AI and Computer Vision.
Score
45
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
42%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in medical imaging market = $1.88 billion in 2025, CAGR 36.91%.
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-09-08
Elucid raises $55M to commercialize cardiovascular imaging platform
medtechdive.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Elucidbio provides a high-value Medical Imaging Dataset, which includes a substantial `image_collection` and corresponding `medical_records`. This dataset is uniquely prepared for Diagnostic AI applications, as it forms the foundation of their own FDA-cleared diagnostic software. Its core value lies in the proprietary, histology-validated ground truth, offering a rare and exceptionally accurate resource for training and validating advanced AI models.
The data serves the rapidly expanding global AI in medical imaging market, a sector valued at $1.88 billion in 2025 and projected to grow at an aggressive CAGR of 36.91%. [4] While access requires navigating complexities such as HIPAA compliance, clinical trial privacy rules, and the data's deep integration into proprietary software, its proven utility and unique validation make it an invaluable asset for buyers aiming to compete in this high-growth market. [4] ⚠ Diligence (valuable data, access to negotiate): Medical data subject to HIPAA and strict clinical trial privacy regulations.; Data is deeply integrated into their FDA-cleared diagnostic software.; Proprietary histology-validated ground truth is their primary competitive moat. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence confirms Elucidbio owns a proprietary, large-scale medical imaging dataset uniquely validated against histology, the clinical gold standard for cardiovascular plaque. This collection is essential for medical AI companies seeking to build and validate next-generation diagnostic AI for identifying high-risk conditions non-invasively. In a market projected to reach $1.88 billion by 2025, this dataset provides the ground truth needed to train algorithms on specific, high-risk plaque features like lipid-rich necrotic core. Acquiring this data offers a significant competitive advantage by accelerating the development of highly accurate, non-invasive diagnostic tools.
See dimension details ↓- Dataset Specificity78
dominant 'medical_records', sector healthcare, 2 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume46
2 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
periodic
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
Buyer demand is extremely high, driven by the explosive growth in the AI in medical imaging market, which is expanding at a 36.91% CAGR. [4]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength50
2 evidence types, 2 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=company_owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 data-appetite signals (2 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 1 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit50
⚠ review — Elucid's core business is selling FDA-cleared AI software that analyzes medical imaging to provide intelligence, which makes it a bad target as it's already a vendor on the market. Issues: Company's core product is selling intelligence/AI software (PlaqueIQ™) to analyze CTA scans, not generating data as a by-product. [4, 6, 8]; The company's business model is based on software licenses and subscriptions for its analysis platform. [4]; The company is defined as a 'medical technology company' or 'AI-based arterial analysis software for providers', not a primary data holder. [1, 2, 9]
- Deep Qualification90
✓ pass — Elucid is a tooling vendor selling FDA-cleared AI software for cardiovascular image analysis; while it possesses a unique histology-validated training dataset, the data generated by its customers remains customer-owned, creating significant access and ownership complexities.
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Image collection
The holder possesses a unique image collection validated against histology, the clinical gold standard, providing unparalleled ground truth for training highly accurate diagnostic models.
Medical records / imaging
This evidence indicates a large-scale dataset of annotated tissue samples used to train proprietary algorithms, crucial for developing AI that can automatically detect high-risk plaque features.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Elucidbio Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in medical imaging market = $1.88 billion in 2025, CAGR 36.91% (source: Fortune Business Insights). [4]. Investment score 45.0/100 (confidence 0.42). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Zetasurgical — Image Dataset Opportunity
View opportunity →healthcareMicrosure — Sensor Telemetry Dataset Opportunity
View opportunity →healthcareDocobo — Medical Imaging Dataset Opportunity
View opportunity →Data Academy
Learn before you deal
- Acquire Rare, Compliant Data3 min read
- Data marketplaces, explained4 min read
- Data licensing, term by term4 min read